论文部分内容阅读
目的:探讨病毒唑超声雾化吸入治疗小儿呼吸道感染的临床效果。方法:选择于2014年1月~2016年1月我院收治的小儿呼吸道感染患儿90例,随机分为观察组和对照组,每组45例,对照组接受常规治疗并静脉滴注病毒唑,观察组在常规治疗的基础上使用病毒唑超声雾化吸入治疗,对比两组临床疗效。结果:1观察组显效27例,有效15例,总有效率93.3%,对照组显效19例,有效16例,总有效率77.8%,组间差异具统计学意义(P<0.05)。2观察组2例患儿乏力,不良反应几率4.4%;对照组9例患者出现不良反应,不良反应几率20.0%,组间差异具统计学意义(P<0.05)。结论:病毒唑超声雾化吸入治疗小儿呼吸道感染安全可靠,有效率高,值得推广。
Objective: To investigate the clinical effect of ultrasonic inhalation of ribavirin on respiratory tract infection in children. Methods: From January 2014 to January 2016, 90 children with respiratory tract infection in our hospital were randomly divided into observation group and control group, with 45 cases in each group. The control group received routine treatment and intravenous infusion of ribavirin , The observation group on the basis of conventional treatment using ribavirin atomization inhalation therapy, compared two groups of clinical efficacy. Results: 1 The observation group was markedly effective in 27 cases, effective in 15 cases, the total effective rate was 93.3%. In the control group, 19 cases were markedly effective and 16 cases were effective. The total effective rate was 77.8%. The difference between the two groups was statistically significant (P <0.05). 2 The observation group 2 patients with fatigue, adverse reaction rate of 4.4%; 9 patients in the control group had adverse reactions, the adverse reaction rate was 20.0%, the difference between the groups was statistically significant (P <0.05). Conclusion: Ribavirin aerosol inhalation for the treatment of pediatric respiratory infections is safe, effective and efficient, which is worth promoting.